Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update
Chronic lymphocytic leukemia (cll) is the most common adult leukemia in North America. In 2018, the first unified national guideline in Canada was developed for the front-line treatment of cll that helped guide treatment across the country. As an update in 2022, a group of clinical experts from acro...
Gespeichert in:
| Veröffentlicht in: | Leukemia research 2023-02, Vol.125, p.107016-107016, Article 107016 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 107016 |
|---|---|
| container_issue | |
| container_start_page | 107016 |
| container_title | Leukemia research |
| container_volume | 125 |
| creator | Owen, Carolyn Banerji, Versha Johnson, Nathalie Gerrie, Alina Aw, Andrew Chen, Christine Robinson, Sue |
| description | Chronic lymphocytic leukemia (cll) is the most common adult leukemia in North America. In 2018, the first unified national guideline in Canada was developed for the front-line treatment of cll that helped guide treatment across the country. As an update in 2022, a group of clinical experts from across Canada came together to provide input and guidance that included new and innovative treatments and approaches that will continue to provide health care professionals with clear guidance on the first-line management of cll. Recommendations were provided in consensus based on available evidence for the first-line treatment of cll.
•Pre-treatment considerations as recommended include IGHV, p53 and Del17p testing.•Watch & Wait is recommended for early stage asymptomatic CLL patients.•Recommendation for patients with TP53 aberrations include BTKi or Ven+O.•Treatment for young/fit patients (no mut del(17p), TP53) includes FCR, BTKi, Ven+O.•Treatment for older or comorbid patients is complex and includes Ven+O, BTKi, chemo. |
| doi_str_mv | 10.1016/j.leukres.2023.107016 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2765772755</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0145212623000012</els_id><sourcerecordid>2765772755</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-bd031a0421ecd60e7182a8a16766c9c9fb41949d5f3bcdc466f7ce809941e2403</originalsourceid><addsrcrecordid>eNqFkLluGzEQhgnDgSU7eYQELNOsTHJ57KYJAsEXYCBNUhNcchhR3kMhuQL09qYsJa2rmfnxz_Uh9JmSFSVU3m5XPcwvEdKKEVYXTRX1Ai1po-pKNLW4REtCuagYZXKBrlPaEkJES9srtKilrLlQaon82ozGBTNi2AcHo4WqMwkc_jOXsg8jYD9F7OM05rcqRzB5gDHjyWO7KXqwuD8Mu81kD_mYl7NgCOYbLocxPO-cyfARffCmT_DpHG_Q7_u7X-vH6vnnw9P6x3NlOWW56hypqSGcUbBOElC0YaYxVCopbWtb33Ha8tYJX3fWWS6lVxYa0racAuOkvkFfT3N3cfo7Q8p6CMlC35sRpjlppmR5mykhilWcrDZOKUXwehfDYOJBU6KPiPVWnxHrI2J9Qlz6vpxXzN0A7n_XP6bF8P1kgPLoPkDUyYYjWRci2KzdFN5Z8QrLPJAa</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2765772755</pqid></control><display><type>article</type><title>Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Owen, Carolyn ; Banerji, Versha ; Johnson, Nathalie ; Gerrie, Alina ; Aw, Andrew ; Chen, Christine ; Robinson, Sue</creator><creatorcontrib>Owen, Carolyn ; Banerji, Versha ; Johnson, Nathalie ; Gerrie, Alina ; Aw, Andrew ; Chen, Christine ; Robinson, Sue</creatorcontrib><description>Chronic lymphocytic leukemia (cll) is the most common adult leukemia in North America. In 2018, the first unified national guideline in Canada was developed for the front-line treatment of cll that helped guide treatment across the country. As an update in 2022, a group of clinical experts from across Canada came together to provide input and guidance that included new and innovative treatments and approaches that will continue to provide health care professionals with clear guidance on the first-line management of cll. Recommendations were provided in consensus based on available evidence for the first-line treatment of cll.
•Pre-treatment considerations as recommended include IGHV, p53 and Del17p testing.•Watch & Wait is recommended for early stage asymptomatic CLL patients.•Recommendation for patients with TP53 aberrations include BTKi or Ven+O.•Treatment for young/fit patients (no mut del(17p), TP53) includes FCR, BTKi, Ven+O.•Treatment for older or comorbid patients is complex and includes Ven+O, BTKi, chemo.</description><identifier>ISSN: 0145-2126</identifier><identifier>EISSN: 1873-5835</identifier><identifier>DOI: 10.1016/j.leukres.2023.107016</identifier><identifier>PMID: 36634577</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adult ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Canada ; Chronic lymphocytic leukemia ; Cll ; Fitness ; Frontline ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis ; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy ; Prognosis ; Treatment</subject><ispartof>Leukemia research, 2023-02, Vol.125, p.107016-107016, Article 107016</ispartof><rights>2023 The Authors</rights><rights>Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-bd031a0421ecd60e7182a8a16766c9c9fb41949d5f3bcdc466f7ce809941e2403</citedby><cites>FETCH-LOGICAL-c412t-bd031a0421ecd60e7182a8a16766c9c9fb41949d5f3bcdc466f7ce809941e2403</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.leukres.2023.107016$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36634577$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Owen, Carolyn</creatorcontrib><creatorcontrib>Banerji, Versha</creatorcontrib><creatorcontrib>Johnson, Nathalie</creatorcontrib><creatorcontrib>Gerrie, Alina</creatorcontrib><creatorcontrib>Aw, Andrew</creatorcontrib><creatorcontrib>Chen, Christine</creatorcontrib><creatorcontrib>Robinson, Sue</creatorcontrib><title>Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update</title><title>Leukemia research</title><addtitle>Leuk Res</addtitle><description>Chronic lymphocytic leukemia (cll) is the most common adult leukemia in North America. In 2018, the first unified national guideline in Canada was developed for the front-line treatment of cll that helped guide treatment across the country. As an update in 2022, a group of clinical experts from across Canada came together to provide input and guidance that included new and innovative treatments and approaches that will continue to provide health care professionals with clear guidance on the first-line management of cll. Recommendations were provided in consensus based on available evidence for the first-line treatment of cll.
•Pre-treatment considerations as recommended include IGHV, p53 and Del17p testing.•Watch & Wait is recommended for early stage asymptomatic CLL patients.•Recommendation for patients with TP53 aberrations include BTKi or Ven+O.•Treatment for young/fit patients (no mut del(17p), TP53) includes FCR, BTKi, Ven+O.•Treatment for older or comorbid patients is complex and includes Ven+O, BTKi, chemo.</description><subject>Adult</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Canada</subject><subject>Chronic lymphocytic leukemia</subject><subject>Cll</subject><subject>Fitness</subject><subject>Frontline</subject><subject>Humans</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</subject><subject>Prognosis</subject><subject>Treatment</subject><issn>0145-2126</issn><issn>1873-5835</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkLluGzEQhgnDgSU7eYQELNOsTHJ57KYJAsEXYCBNUhNcchhR3kMhuQL09qYsJa2rmfnxz_Uh9JmSFSVU3m5XPcwvEdKKEVYXTRX1Ai1po-pKNLW4REtCuagYZXKBrlPaEkJES9srtKilrLlQaon82ozGBTNi2AcHo4WqMwkc_jOXsg8jYD9F7OM05rcqRzB5gDHjyWO7KXqwuD8Mu81kD_mYl7NgCOYbLocxPO-cyfARffCmT_DpHG_Q7_u7X-vH6vnnw9P6x3NlOWW56hypqSGcUbBOElC0YaYxVCopbWtb33Ha8tYJX3fWWS6lVxYa0racAuOkvkFfT3N3cfo7Q8p6CMlC35sRpjlppmR5mykhilWcrDZOKUXwehfDYOJBU6KPiPVWnxHrI2J9Qlz6vpxXzN0A7n_XP6bF8P1kgPLoPkDUyYYjWRci2KzdFN5Z8QrLPJAa</recordid><startdate>202302</startdate><enddate>202302</enddate><creator>Owen, Carolyn</creator><creator>Banerji, Versha</creator><creator>Johnson, Nathalie</creator><creator>Gerrie, Alina</creator><creator>Aw, Andrew</creator><creator>Chen, Christine</creator><creator>Robinson, Sue</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202302</creationdate><title>Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update</title><author>Owen, Carolyn ; Banerji, Versha ; Johnson, Nathalie ; Gerrie, Alina ; Aw, Andrew ; Chen, Christine ; Robinson, Sue</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-bd031a0421ecd60e7182a8a16766c9c9fb41949d5f3bcdc466f7ce809941e2403</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adult</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Canada</topic><topic>Chronic lymphocytic leukemia</topic><topic>Cll</topic><topic>Fitness</topic><topic>Frontline</topic><topic>Humans</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</topic><topic>Prognosis</topic><topic>Treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Owen, Carolyn</creatorcontrib><creatorcontrib>Banerji, Versha</creatorcontrib><creatorcontrib>Johnson, Nathalie</creatorcontrib><creatorcontrib>Gerrie, Alina</creatorcontrib><creatorcontrib>Aw, Andrew</creatorcontrib><creatorcontrib>Chen, Christine</creatorcontrib><creatorcontrib>Robinson, Sue</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Leukemia research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Owen, Carolyn</au><au>Banerji, Versha</au><au>Johnson, Nathalie</au><au>Gerrie, Alina</au><au>Aw, Andrew</au><au>Chen, Christine</au><au>Robinson, Sue</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update</atitle><jtitle>Leukemia research</jtitle><addtitle>Leuk Res</addtitle><date>2023-02</date><risdate>2023</risdate><volume>125</volume><spage>107016</spage><epage>107016</epage><pages>107016-107016</pages><artnum>107016</artnum><issn>0145-2126</issn><eissn>1873-5835</eissn><abstract>Chronic lymphocytic leukemia (cll) is the most common adult leukemia in North America. In 2018, the first unified national guideline in Canada was developed for the front-line treatment of cll that helped guide treatment across the country. As an update in 2022, a group of clinical experts from across Canada came together to provide input and guidance that included new and innovative treatments and approaches that will continue to provide health care professionals with clear guidance on the first-line management of cll. Recommendations were provided in consensus based on available evidence for the first-line treatment of cll.
•Pre-treatment considerations as recommended include IGHV, p53 and Del17p testing.•Watch & Wait is recommended for early stage asymptomatic CLL patients.•Recommendation for patients with TP53 aberrations include BTKi or Ven+O.•Treatment for young/fit patients (no mut del(17p), TP53) includes FCR, BTKi, Ven+O.•Treatment for older or comorbid patients is complex and includes Ven+O, BTKi, chemo.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>36634577</pmid><doi>10.1016/j.leukres.2023.107016</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0145-2126 |
| ispartof | Leukemia research, 2023-02, Vol.125, p.107016-107016, Article 107016 |
| issn | 0145-2126 1873-5835 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2765772755 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Adult Antineoplastic Combined Chemotherapy Protocols - therapeutic use Canada Chronic lymphocytic leukemia Cll Fitness Frontline Humans Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Prognosis Treatment |
| title | Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T17%3A43%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Canadian%20evidence-based%20guideline%20for%20frontline%20treatment%20of%20chronic%20lymphocytic%20leukemia:%202022%20update&rft.jtitle=Leukemia%20research&rft.au=Owen,%20Carolyn&rft.date=2023-02&rft.volume=125&rft.spage=107016&rft.epage=107016&rft.pages=107016-107016&rft.artnum=107016&rft.issn=0145-2126&rft.eissn=1873-5835&rft_id=info:doi/10.1016/j.leukres.2023.107016&rft_dat=%3Cproquest_cross%3E2765772755%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2765772755&rft_id=info:pmid/36634577&rft_els_id=S0145212623000012&rfr_iscdi=true |